Synergistic activity of carfilzomib and panobinostat in multiple myeloma cells via modulation of ROS generation and ERK1/2

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Gao, Lu ^a   Gao, Minjie ^a   Yang, Guang ^a   Tao, Yi ^a   Kong, Yuanyuan ^a   Yang, Ruixue ^a   Meng, Xiuqin ^a   Ai, Gongwen ^a   Wei, Rong ^a   Wu, Huiqun ^a   Wu, Xiaosong ^a   Shi, Jumei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CARFILZOMIB; CASPASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PANOBINOSTAT; REACTIVE OXYGEN METABOLITE; HYDROXAMIC ACID; INDOLE DERIVATIVE; OLIGOPEPTIDE;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; MULTIPLE MYELOMA; OXIDATIVE STRESS; CELL SURVIVAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; HYDROXAMIC ACIDS; INDOLES; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPLE MYELOMA; OLIGOPEPTIDES; REACTIVE OXYGEN SPECIES;

EID: 84929376506     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/459052     Document Type: Article

References (24)

1. S. Genadieva-Stavric, F. Cavallo, and A. Palumbo, "New approaches to management of multiple myeloma, " Current Treatment Options in Oncology, vol. 15, no. 2, pp. 157-170, 2014.
2. X.-Y. Pei, Y. Dai, and S. Grant, "Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors, " Clinical Cancer Research, vol. 10, no. 11, pp. 3839-3852, 2004.
3. D. M. Weber, T. Graef, M. Hussein et al., "Phase i trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma, " Clinical Lymphoma, Myeloma and Leukemia, vol. 12, no. 5, pp. 319-324, 2012.
4. K. Fostier, A. de Becker, and R. Schots, "Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma, " Onco-Targets andTherapy, vol. 5, pp. 237-244, 2012.
5. P. Moreau, "The emerging role of carfilzomib combination therapy in the management of multiple myeloma, " Expert Review of Hematology, vol. 7, no. 2, pp. 265-290, 2014.
6. J. R. Berenson, J. D. Hilger, O. Yellin et al., "Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy, " Leukemia, vol. 28, no. 7, pp. 1529-1536, 2014.
7. P. Neri, N. J. Bahlis, and S. Lonial, "Panobinostat for the treatment of multiple myeloma, " Expert Opinion on Investigational Drugs, vol. 21, no. 5, pp. 733-747, 2012.
8. A. Khot, M. Dickinson, and H. M. Prince, "Panobinostat in lymphoid and myeloid malignancies, " Expert Opinion on Investigational Drugs, vol. 22, no. 9, pp. 1211-1223, 2013.
9. J. F. San-Miguel, P. G. Richardson, A. Günther et al., "Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma, " Journal of Clinical Oncology, vol. 31, no. 29, pp. 3696-3703, 2013.
10. J. R. Berenson, J. D. Hilger, O. Yellin et al., "A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma, " Annals of Hematology, vol. 93, no. 1, pp. 89-98, 2014.
11. P. G. Richardson, R. L. Schlossman, M. Alsina et al., "PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma, " Blood, vol. 122, no. 14, pp. 2331-2337, 2013.
12. R. Feng, A. Oton, M. Y. Mapara, G. Anderson, C. Belani, and S. Lentzsch, "The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage, " The British Journal of Haematology, vol. 139, no. 3, pp. 385-397, 2007.
13. T. Hideshima, J. E. Bradner, J. Wong et al., "Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8567-8572, 2005.
14. S. Bhalla, S. Balasubramanian, K. David, and et al, "PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-κB mechanisms and is synergistic with bortezomib in lymphoma cells, " Clinical Cancer Research, vol. 15, no. 14, pp. 3354-3365, 2009.
15. R. Castelli, R. Gualtierotti, N. Orofino, A. Losurdo, S. Gandolfi, and M. Cugno, "Current and emerging treatment options for patients with relapsed myeloma, " Clinical Medicine Insights: Oncology, vol. 7, pp. 209-219, 2013.
16. L. Bastian, J. Hof, M. Pfau et al., "Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB, " Clinical Cancer Research, vol. 19, no. 6, pp. 1445-1457, 2013.
17. A. Fribley, Q. Zeng, and C.-Y. Wang, "Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells, "Molecular and Cellular Biology, vol. 24, no. 22, pp. 9695-9704, 2004.
18. Y.-H. Ling, L. Liebes, Y. Zou, and R. Perez-Soler, "Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 Non-small cell lung cancer cells, " The Journal of Biological Chemistry, vol. 278, no. 36, pp. 33714-33723, 2003.
19. R. R. Rosato, S. S. Kolla, S. K. Hock et al., "Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway, " The Journal of Biological Chemistry, vol. 285, no. 13, pp. 10064-10077, 2010.
20. J. S. Ungerstedt, Y. Sowa, W.-S. Xu et al., "Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 3, pp. 673-678, 2005.
21. M. Gao, L. Gao, Y. Tao et al., "Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells, " Acta Biochimica et Biophysica Sinica, vol. 46, no. 6, pp. 484-491, 2014.
22. G. Dasmahapatra, D. Lembersky, M. P. Son et al., "Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo, " Molecular CancerTherapeutics, vol. 10, no. 9, pp. 1686-1697, 2011.
23. X. Wang, J. L. Martindale, Y. Liu, and N. J. Holbrook, "The cellular response to oxidative stress: influences of mitogenactivated protein kinase signalling pathways on cell survival, " The Biochemical Journal, vol. 333, no. part 2, pp. 291-300, 1998.
24. Q.-L. Zhang, L. Wang, Y.-W. Zhang et al., "The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis, " Leukemia, vol. 23, no. 8, pp. 1507-1514, 2009.